SAD and Single-Dose Study of JNJ-75105186 in Healthy Japanese and Chinese Participants

Phase 1, randomised, double-blind trial comparing JNJ-75105186 with Placebo (2 arms). Primary endpoints: Number of participants with adverse events as a measure of safety and tolerability (Part 1 and Part 2) and Plasma concentration of JNJ-75105186 predose up to 48 hours postdose (Part 1 and Part 2). Started Nov 2021; status: active, not recruiting.